Itaconix (ITX LN) Agreement with AkzoNobel to develop bio-based chelates | Itaconix (ITX LN) Agreement with AkzoNobel to develop bio-based chelates | Severfield (SFR LN) In line AGM statement | Summit Therapeutics (SUMM LN) Exploratory data supports ridinilazole’s selectivity | Synairgen (SNG LN) Lead LOXL2 compound on track to commence Phase I in Q4 2017 | Vectura Group (VEC LN) H1 results in line, but flutiform® destocking a concern for H2 | Xaar (XAR LN) Interim results in line; transformatio ....
06 Sep 2017
N+1 Singer - Morning Song 06-09-2017
Xaar plc (XAR:LON), 117 | Synairgen plc (SNG:LON), 6.7 | Itaconix plc (ITX:LON), 153 | Severfield Plc (SFR:LON), 68.6 | ReNeuron Group plc (RENE:LON), 3.0 | Summit Therapeutics Inc (SMMT:NAS), 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Morning Song 06-09-2017
Xaar plc (XAR:LON), 117 | Synairgen plc (SNG:LON), 6.7 | Itaconix plc (ITX:LON), 153 | Severfield Plc (SFR:LON), 68.6 | ReNeuron Group plc (RENE:LON), 3.0 | Summit Therapeutics Inc (SMMT:NAS), 0
- Published:
06 Sep 2017 -
Author:
N+1 Singer Team -
Pages:
15
Itaconix (ITX LN) Agreement with AkzoNobel to develop bio-based chelates | Itaconix (ITX LN) Agreement with AkzoNobel to develop bio-based chelates | Severfield (SFR LN) In line AGM statement | Summit Therapeutics (SUMM LN) Exploratory data supports ridinilazole’s selectivity | Synairgen (SNG LN) Lead LOXL2 compound on track to commence Phase I in Q4 2017 | Vectura Group (VEC LN) H1 results in line, but flutiform® destocking a concern for H2 | Xaar (XAR LN) Interim results in line; transformatio ....